SITANOW-M 500

Description:

• SITANOW-M 500 combines sitagliptin 50 mg and metformin hydrochloride 500 mg to provide a dual mechanism approach for improving glycemic control in adults with type 2 diabetes mellitus. This combination targets both insulin resistance and impaired insulin secretion.
• As trusted sitagliptin tablet suppliers and metformin tablets distributors, we ensure high-quality formulations and consistent supply to healthcare systems worldwide. Our footprint extends across global markets as sitagliptin wholesalers, making us a reliable source for bulk procurement. For dosage-specific demand, we also operate as a sitagliptin tablets 50mg supplier, catering to targeted therapy needs.

Key Features:

• Synergistic action of sitagliptin and metformin addresses multiple defects in glucose regulation.
• Effective in reducing HbA1c levels and controlling postprandial glucose excursions.
• Weight-neutral or modest weight loss observed, beneficial for overweight individuals.
• Twice-daily dosing aligns with meal times to enhance glycemic control.
• Suitable for patients inadequately controlled on monotherapy or requiring combination therapy.

Usage Guidelines:

• Administer one tablet twice daily with meals to reduce gastrointestinal side effects.
• Appropriate for adults with type 2 diabetes needing improved glycemic control.
• Monitor renal function before initiating therapy and periodically during treatment.

Safety Profile:

• Gastrointestinal symptoms such as nausea or diarrhea may occur, especially during initiation.
• Contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, or significant renal impairment.

Use with caution in patients with hepatic dysfunction or those at risk for lactic acidosis.
 

Uses / Indications: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.